Details of the Drug

General Information of Drug (ID: DM9R1YU)

Drug Name
Gestodene
Synonyms
Gestinol; Gestoden; Gestodene [USAN:INN:BAN]; Gestodeno; Gestodeno [INN-Spanish]; Gestodenum; Gestodenum [INN-Latin]; SH B 331; GESTODENE; 13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregna-4,15-dien-20-yn-3-one; 1664P6E6MI; 17-alpha-Ethinyl-13-ethyl-17-beta-hydroxy-4,15-gonadien-3-one; 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17-alpha)-; 60282-87-3; BRN 4237181; CCRIS 9189; DSSTox_CID_26478; DSSTox_GSID_46478; DSSTox_RID_81649; EINECS 262-145-8; HSDB 3594; UNII-1664P6E6MI
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 310.4
Logarithm of the Partition Coefficient (xlogp) 2.9
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Bioavailability
93% of drug becomes completely available to its intended biological destination(s) [1]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.8 mL/min/kg [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 16 - 18 hours [2]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.0046 micromolar/kg/day [3]
Unbound Fraction
The unbound fraction of drug in plasma is 0.023% [2]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.46 L/kg [2]
Chemical Identifiers
Formula
C21H26O2
IUPAC Name
(8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14-decahydrocyclopenta[a]phenanthren-3-one
Canonical SMILES
CCC12CCC3C(C1C=CC2(C#C)O)CCC4=CC(=O)CCC34
InChI
InChI=1S/C21H26O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,10,12-13,16-19,23H,3,5-9,11H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1
InChIKey
SIGSPDASOTUPFS-XUDSTZEESA-N
Cross-matching ID
PubChem CID
3033968
ChEBI ID
CHEMBL135323
CAS Number
60282-87-3
UNII
1664P6E6MI
DrugBank ID
DB06730
INTEDE ID
DR0770
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Vitamin K-dependent protein S (PROS1) OTXQWNOI PROS_HUMAN Gene/Protein Processing [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
4 Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1'-hydroxylation. Br J Clin Pharmacol. 2000 Oct;50(4):333-7.
5 Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol. 2003 Jun 1;23(6):1116-21. doi: 10.1161/01.ATV.0000074146.36646.C8. Epub 2003 May 1.